Skip to main content
SpringerLink
Log in

Active vitamin D metabolites in glucocorticoid-induced osteoporosis

  • Satellite Symposium on New Aspects in Therapy With Active Vitamin D Derivatives May 19, 1996 Amsterdam, The Netherlands
  • Published:
Calcified Tissue International Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Reid IR, Grey AB (1993) Corticosteroid osteoporosis. Baillières Clin Rheumatol 7:573–587

    Article  CAS  PubMed  Google Scholar 

  2. Lukert BP, Raisz LG (1994) Glucocorticoid-induced osteoporosis. Rheum Dis Clin North Am 20:629–650

    CAS  PubMed  Google Scholar 

  3. Ringe JD (1991) Sekundäre Osteoporosen. In: Ringe JD (ed) Osteoporose pathogenese, diagnostik und therapiemöglichkeiten Walter de Gruyter, Berlin, New York, pp 409–483

    Google Scholar 

  4. Ringe JD, Dorst A (1993) Osteoporosis in males: pathogenesis and clinical classification. In: Christiansen C, Riis B (eds) Pathogenesis. Proc 4th Int Symp Osteoporosis, Hong Kong, pp 184–185

  5. Ringe JD (1995) Osteoporose. Postmenopausale Osteoporose, Senile Osteoporose, Sekundäre Osteoporose, Osteoporose des Mannes. Georg Thieme Verlag, Stuttgart, New York

    Google Scholar 

  6. Epstein S, Shane E, Bilezikian JP (1995) Organ transplantation and osteoporosis. Curr Opinion Rheumatol 7:255–261

    Article  CAS  Google Scholar 

  7. Jones SM, Bhalla AK (1993) Osteoporosis in rheumatoid arthritis. Clin Exp Rheumatol 11:557–562

    CAS  PubMed  Google Scholar 

  8. Gough AKS, Lilley J, Eyre S, Holder RL, Emery P (1994) Generalised bone loss in patients with early rheumatoid arthritis. Lancet 344:23–27

    Article  CAS  PubMed  Google Scholar 

  9. Roux C, Abitbol V, Chaussade S, Kolta S, Guillemant S, Dougados M, Amor B, Couturier D (1995) Bone loss in patients with inflammatory bowel disease: prospective study. Osteoporosis Int 5:156–160

    Article  CAS  Google Scholar 

  10. Compston JE, Audran M, Avouac B, Bouvenot G, Devoglaer JP, Eastell R, Fabris F, Gennari C, Jones EA, Kaufman JM, Lemmel E-M, Mazzuoli G, Reid D, Ringe JD, Vanhaelst L, Ziegler R, Reginster JY (1996) Proposals for the evaluation of agents used in the prevention and treatment of glucocorticoidinduced osteoporosis. Calcif Tissue Int (in press)

  11. Gennari C (1985) Glucocorticoids and bone. In: Peck WA (ed) Bone and mineral research/3. Elsevier. Amsterdam, pp 213–231

    Google Scholar 

  12. Reid IR, Evans MC, Wattie DJ (1992) Bone mineral density of the proximal femur and lumbar spine in glucocorticoid-treated asthmatic patients. Osteoporosis Int 2:103–105

    Article  CAS  Google Scholar 

  13. Ringe JD, Meunier PJ (1995) What is the future for fluoride in the treatment of osteoporosis? Osteoporosis Int 5:71–74

    Article  CAS  Google Scholar 

  14. Rizzoli R, Chevalley Th, Slosman DO, Bonjour J-Ph (1995) Sodium monofluorophosphate increases vertebral bone mineral density in patients with corticoid-induced osteoporosis. Osteoporosis Int 5:39–46

    Article  CAS  Google Scholar 

  15. Meys E, Terraux-Duvert F, Beaume-Six T, Dureau G, Meunier PJ (1993) Bone loss after cardiac transplantation: effects of calcium, calcidiol and monofluorophosphate. Osteoporosis Int 3:1–8

    Article  Google Scholar 

  16. Reid IR, Ibbertson HK (1986) Calcium supplements in the prevention of steroid-induced osteoporosis. Am J Clin Nutr 44:287–290

    CAS  PubMed  Google Scholar 

  17. Ringe JD, Welzel D (1987) Salmon calcitonin in the therapy of corticoid-induced osteoporosis. Eur J Clin Pharmacol 33: 35–39

    Article  CAS  PubMed  Google Scholar 

  18. Reid IR, King AR, Alexander CJ, Ibbertson HK (1988) Prevention of steroid-induced osteoporosis with (3-amino-l-hydroxypropylidene)-l, lbisphosphonate (APD). Lancet i: 143–146

    Article  Google Scholar 

  19. Lukert BP, Johnson BE, Robinson RG (1992) Estrogen and progesterone replacement therapy reduces glucocorticoid-induced bone loss. J Bone Miner Res 7:1063–1069

    Article  CAS  PubMed  Google Scholar 

  20. Sambrook P, Birmingham J, Kelly P, Kempler S, Nguyen T, Pocock N, Eisman J (1993) Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin. N Engl J Med 328:1747–1752

    Article  CAS  PubMed  Google Scholar 

  21. Struys A, Snelder AA, Mulder H (1995) Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis. Am J Med 99:235–242

    Article  CAS  PubMed  Google Scholar 

  22. Olbricht T, Benker G (1993) Glucocorticoid-induced osteoporosis: pathogenesis, prevention, and treatment with special regard to the rheumatic diseases. J Int Med 234:237–244

    Article  CAS  Google Scholar 

  23. Magaro M, Tricerri A, Piane D, Zoli A, Serra F, Altomonte F, Mirone L (1991) Generalized osteoporosis in non-steroidtreated rheumatoid arthritis. Rheumatol Int 11:73–76

    Article  CAS  PubMed  Google Scholar 

  24. Lane NE, Pressman AR, Star VL, Cummings SR, Nevitt MC (1995) Rheumatoid arthritis and bone mineral density in elderly women. J Bone Miner Res 10:257–263

    Article  CAS  PubMed  Google Scholar 

  25. Nielsen HK, Charles P, Mosekilde L (1988) The effect of single oral doses of prednisone on the circadian rhythm of serum osteocalcin in normal subjects. J Clin Endocrinol Metab 67:1025

    Article  CAS  PubMed  Google Scholar 

  26. Lund B, Andersen RB, Friis T, Hjorth L, Jorgensen FS, Norman AW, Sorensen OH (1977) Effect of 1-alphahydroxyvitamin D3 and 1.25-dihydroxyvitamin D3 on intestine and bone in glucocorticoid-treated patients. Clin Endocrinol 7:177s-181s

    Article  Google Scholar 

  27. Hahn TJ, Halstead LR, Teitelbaum SL (1979) Altered mineral metabolism in glucocorticoid-induced osteopenia. Effect of 25-hydroxyvitamin D administration. J Clin Invest 64:655–665

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  28. Malluche HH, Faugere MC, Friedler RM, Fanti P (1988) 1,25-dihydroxyvitamin D3 corrects bone loss but suppresses bone remodeling in ovariohysterectomized beagle dogs. Endocrinology 122:1998–2006

    Article  CAS  PubMed  Google Scholar 

  29. Tsurukami H, Nakamura T, Suzuki K, Sato K, Higuchi Y, Nishii Y (1994) A novel synthetic vitamin D analogue, 2β-(3-hydroxypropoxy) 1,25-dihydroxyvitamin D3 (ED-71), increases bone mass by stimulating the bone formation in normal and ovariectomized rats. Calcif Tissue Int 54:142–149

    Article  CAS  PubMed  Google Scholar 

  30. Liesegang P, Romalo G, Sudmann M, Wolf L, Schweikert H-U (1994) Human osteoblast-like cells contain specific, saturable, high-affinity glucocorticoid, androgen, estrogen and 1,25-dihydroxycholecalciferol receptors. J Andrology 15: 194–199

    CAS  Google Scholar 

  31. Ishibe M, Nojima T, Ishibashi T, Koda T, Kaneda K, Rosier RN, Puzas JE (1995) 17β-estradiol increases the receptor number and modulates the action of 1,25-dihydroxyvitamin D3 in human osteosarcoma-derived osteoblast-like cells. Calcif Tissue Int 57:430–435

    Article  CAS  PubMed  Google Scholar 

  32. Jowel PS, Epstein S, Fallon MD, Reinhardt TA, Ismail F (1987) 1,25-dihydroxyvitamin D3 modulates glucocorticoid-induced alteration in serum bone Gla protein and bone histomorphometry. Endocrinology 120:531–536

    Article  Google Scholar 

  33. Nielsen HK, Brixen K, Kassem M, Mosekilde L (1991) Acute effect of 1,25-dihydroxyvitamin D3, prednisone, and 1,25-dihydroxyvitamin D3 plus prednisone on serum osteocalcin in normal individuals. J Bone Min Res 6:435–440

    Article  CAS  Google Scholar 

  34. Nishii Y (1993) Future prospects for vitamin D analogues: overview. Potts JT, Ogata E (eds) Proc Intern Bone Forum Nov. 4–5, 1993, Yokohama, Japan

    Google Scholar 

  35. Mathieu C, Laureys J, Waer M, Bouillon R (1994) Prevention of autoimmune destruction of transplant islets in spontaneously diabetic NOD mice by KH1060, a 20-Epi analog of vitamin D: synergy with cyclosporin. Transplant Proc 26: 3128–3129

    CAS  PubMed  Google Scholar 

  36. Lempert UG, Minne HW, Albrecht B, Scharla SH, Matthes E, Ziegler R (1989) 1,25-dihydroxyvitamin D3 prevents the decrease of bone mineral appositional rate in rats with inflammation-mediated osteopenia (IMO). Bone Min 7:149–158

    Article  CAS  Google Scholar 

  37. Mathieu C, Waer M, Laureys J, Rutgeerts O, Bouillon R (1994) Activated form of vitamin D (1,25-(OH)2-D3) and its analogues are dose-reducing agents for cyclosporine in vitro and in vivo. Transplant Proc 26:3048–3049

    CAS  PubMed  Google Scholar 

  38. Geusens P, Dequeker J, Nijs J, Verstraeten A, Bramm E (1991) Prevention and treatment of osteopenia in the ovariectomized rat: effect of combined therapy with estrogens, 1-al-pha vitamin D and prednisone. Calcif Tissue Int 48:127–137

    Article  CAS  PubMed  Google Scholar 

  39. Aerssens J, van Audekercke R, Talalaj M (1994) Effect of 1 alpha-vitamin D3 on bone strength and composition in growing rats with and without corticosteroid treatment. Calcif Tissue Int 55:443–450

    Article  CAS  PubMed  Google Scholar 

  40. Tanaka Y, Nakamura T, Nishida S, Suzuki K, Takeda S, Sato K, Nishii Y (1996) Effects of synthetic vitamin D analog, ED-71, on bone dynamics and strength in cancellous and cortical bone in prednisolone-treated rats. J Bone Miner Res 11: 325–336

    Article  CAS  PubMed  Google Scholar 

  41. Dykman TR, Haralson KM, Gluck OS, Murphy WA, Teitelbaum SL, Hahn TJ, Hahn BH (1984) Effect of oral 1,25-dihydroxyvitamin D and calcium on glucocorticoid-induced osteopenia in patients with rheumatic disease. Arthritis Rheum 27:1336–1343

    Article  CAS  PubMed  Google Scholar 

  42. Neuhaus R, Lohmann R, Platz KP, Guckelberger O, Schön M, Hierholzer J, Neuhaus P (1995) Treatment of osteoporosis after liver transplantation. Transplant Proc 27:1226–1227

    CAS  PubMed  Google Scholar 

  43. Graf H, Stummvoll HK, Kovarik J, Bergmann H (1980) Aktive Vitamin-D-Metabolite in der Therapie der Cortisonosteoporose. Wiener Klin Wschr 92:776–777

    Google Scholar 

  44. Braun JJ, Birkenhäger-Frenkel DH, Rietveld AH, Juttmann JR, Visser TJ, Birkenhäger JC (1983) Influence of lalpha-(OH)D3 administration on bone and bone mineral metabolism in patients on chronic glucocorticoid treatment: a double-blind controlled study. Clin Endocrinol 18:265–273

    Article  Google Scholar 

  45. Verstraeten A, Dequeker J, Nijs J, Geusens P (1989) Prevention of postmenopausal bone loss in rheumatoid arthritis patients. A two-year prospective study. Clin Exper Rheumatol 7:351–358

    CAS  Google Scholar 

  46. Yamada H (1989) Long-term effect of 1 alpha-hydroxy vitamin D, calcium and thiazide administration on glucocorticoidinduced osteoporosis. Nippon Naibunpi Gakkai Zasshi 65: 603–614

    CAS  PubMed  Google Scholar 

  47. Van Cleemput J, Daenen W, Guesens P, Dequeker J, Van de Werf F, Vanhaecke J (1996) Prevention of bone loss in cardiac transplant recipients. Transplantation 61(10): 1495–1499

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinikum Leverkusen Akadem. Lehrkrankenhaus, University of Cologne, D-51375, Leverkusen, Germany

    J. D. Ringe

Authors
  1. J. D. Ringe
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ringe, J.D. Active vitamin D metabolites in glucocorticoid-induced osteoporosis. Calcif Tissue Int 60, 124–127 (1997). https://doi.org/10.1007/s002239900200

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s002239900200

Keywords

Search

Navigation